Ahfs di. AHFS Classification

Off

ahfs di

Special Populations Describes specific absorption characteristics e. Morrow L, Hompesch M, Guthrie H et al. Generally, potential interactions supported only by animal or in vitro data are not described. Rate of Administration For injectable drugs and other dosage forms, this subsection describes the recommended rates of administration e. No difference in pregnancy outcomes or the health of the fetus and newborn with insulin detemir use.

Next

AHFS DI Essentials Users Guide Monograph for Professionals

ahfs di

Occasionally, instructions for extemporaneous preparation of a dosage form that is not commercially available e. Individual monographs may not contain all of the information described below, and the absence of specific information within an individual monograph does not imply that such information is unavailable. Special Populations When available and applicable, specific dosages for special populations e. The initial and maintenance dosages are given. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Sub-Q Administration Administer by sub-Q injection once or twice daily using a conventional insulin syringe or an injection pen i.

Next

Levemir Monograph for Professionals

ahfs di

Insulin detemir: a long-acting insulin product. Comparisons with other forms of therapy and limitations on use are included when appropriate. The effect of peritoneal dialysis and hemodialysis on elimination of the drug also is discussed. See Geriatric Patients under Dosage and Administration. Prophylaxis in Patients with Blepharitis or Vaccinia Lesions On or Near the Eyelid Ophthalmic Instill 1 drop of 1% ophthalmic solution in the affected eye every 4 hours while awake i.

Next

AHFS Classification

ahfs di

The information may include a general discussion and several tables organized by solution compatibility, drug compatibility, and Y-site compatibility. When the drug is administered during pregnancy or if the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus. Trifluridine Pharmacokinetics Absorption Bioavailability Systemic absorption following topical application of trifluridine 1% ophthalmic solution appears to be negligible. Common Adverse Effects Mild, transient burning, stinging, or local irritation upon instillation, palpebral edema. Stability Storage Ophthalmic Solution 2—8°C. Russell-Jones D, Simpson R, Hylleberg B et al.

Next

AHFS Drug Information

ahfs di

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Administration The Administration subsection describes the routes of administration and, when necessary for clarity, the appropriate dosage form for each route. Pregnant women with type 1 diabetes mellitus: nasopharyngitis, headache, anemia, diarrhea, preeclampsia, urinary tract infection, gastroenteritis, upper abdominal pain, vomiting, spontaneous abortion, abdominal pain, oropharyngeal pain. If you are using your device's web browser, then, yes, you need an active Internet connection. Information in the compatibility section summarizes complex information from multiple sources in an easy-to-use, reliable format.

Next

AHFS DI

ahfs di

Hyperglycemic crises in adult patients with diabetes mellitus: a consensus statement from the American Diabetes Association. Stability Storage Parenteral Injection Unopened vials, and FlexTouch injection pens: 2—8°C; store in carton to protect from light. Hepatic Impairment Describes specific precautions applicable to patients with impaired hepatic function. Do not mix with any other insulin or solutions. Vaccinia Virus Ophthalmic Infections Topical treatment and prophylaxis of ocular vaccinia infections that occur as a complication of smallpox vaccination in the vaccine recipient or close contact.

Next

AHFS Drug Information

ahfs di

Only a small amount of information on compatibility of drugs mixed in the same syringe is included; consult specialized references for additional information. Q: How do I change my password? Those situations or conditions for which the drug should not be used because the risk clearly outweighs any possible benefit also are described. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Also includes information on various applicable dosages and regimens. Compatibility and stability information is described under the Stability section toward the end of the monograph. Plasma Protein Binding Describes extent of drug binding to plasma proteins e.

Next